BMI

An apple cider vinegar drink a day? New study shows it might help weight loss

Retrieved on: 
Wednesday, March 13, 2024
Paper, Fever, Diet, Overweight, Cholesterol, Record, Dentist, Acetic acid, Blood, News, Weight loss, Tooth enamel, Exercise, Food, Human, Risk, Mouth, Triglyceride, Saliva, Drinking, Lactic acid, BMI, Apple, Clinical trial, Gene, Motivation, Science, Taste, Body mass index, Ageing, Research, Water, Wine

An experimental study, released today, looks into whether apple cider vinegar could be effective for weight loss, reduce blood glucose levels and reduce blood lipids (cholesterol and triglycerides).

Key Points: 
  • An experimental study, released today, looks into whether apple cider vinegar could be effective for weight loss, reduce blood glucose levels and reduce blood lipids (cholesterol and triglycerides).
  • The results suggest it could reduce all three – but it might not be as simple as downing an apple cider vinegar drink a day.

What did they do?

  • A control group consumed an inactive drink (a placebo) made (from lactic acid added to water) to look and taste the same.
  • The study was also double-blinded, which means neither the participants or the scientists involved with collecting the data knew who was in which group.

So, what did they find?

  • After a period of three months apple cider vinegar consumption was linked with significant falls in body weight and body mass index (BMI).
  • On average, those who drank apple cider vinegar during that period lost 6–8kg in weight and reduced their BMI by 2.7–3 points, depending on the dose.
  • The authors also report significant decreases in levels of blood glucose, triglycerides, and cholesterol in the apple cider groups.

Is this good news?

  • Firstly, study participants were aged from 12 to 25, so we can’t say whether the results could apply to everyone.
  • And while the researchers kept records of the participants’ diet and exercise during the study, these were not published in the paper.
  • This could be important and influence results if people who did not lose weight quit due to lack of motivation.


Read more:
Turns out the viral 'Sleepy Girl Mocktail' is backed by science. Should you try it?

Any other concerns?


Apple cider vinegar is acidic and there are concerns it may erode tooth enamel. This can be a problem with any acidic beverages, including fizzy drinks, lemon water and orange juice. To minimise the risk of acid erosion some dentists recommend the following after drinking acidic drinks:

Read more:
Apple cider vinegar: is drinking this popular home remedy bad for your teeth? A dentist explains

Down the hatch?

  • This study provides us with some evidence of a link between apple cider vinegar and weight loss.
  • This would provide more robust evidence that apple cider vinegar could be a useful aid for weight loss.


Evangeline Mantzioris is affiliated with Alliance for Research in Nutrition, Exercise and Activity (ARENA) at the University of South Australia. Evangeline Mantzioris has received funding from the National Health and Medical Research Council, and has been appointed to the National Health and Medical Research Council Dietary Guideline Expert Committee.

MaNaDr's Weight Management Program Makes Waves at World Obesity Day Walk 2024 in Singapore

Retrieved on: 
Friday, March 8, 2024
Health, Telehealth, Weight loss, World Obesity Day, Attention, Gold, BMI, Patient, Prescription, Nursing

MaNaDr, the gold event sponsor, believes more than 500 attendees visited its’ booth to inquire about the weight management program.

Key Points: 
  • MaNaDr, the gold event sponsor, believes more than 500 attendees visited its’ booth to inquire about the weight management program.
  • “We were thrilled by the enthusiasm and level of engagement surrounding weight management at the event,” said MaNaDr chief executive officer and co-founder Dr. Siaw Tung Yeng.
  • Second, all our doctors in the program are certified family physicians with Singapore’s latest Basic Obesity Management Accreditations.
  • These activities are part of the global World Obesity Day, an annual event started in 2015 to increase worldwide awareness of obesity.

ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV

Retrieved on: 
Tuesday, March 5, 2024
Infection, Liver, Bangladesh Technical Education Board, Metabolism, Woman, P.T, Fungal infection, NIAID, Prediabetes, CROI, Liver injury, Inflammation, Quality of life, ACTG, ALT, Weight loss, Waist, Weight, Organ dysfunction, University of Southern California, Conference, Health, Glucagon-like peptide-1 receptor, University, SLIM, ART, Triglyceride, BMI, UM1, Insulin resistance, HIV, Non-alcoholic fatty liver disease, Research, University of North Carolina, Dietary supplement

Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.

Key Points: 
  • Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.
  • Together, these presentations demonstrate that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV.
  • SLIM LIVER is the first study evaluating semaglutide as a treatment for MASLD among people living with HIV.
  • MASLD is common among people living with HIV and likely acts synergistically with HIV to accelerate liver injury and organ dysfunction.

REMSleep Holdings Shareholder Update

Retrieved on: 
Monday, March 4, 2024
ISO, Blood pressure, Incidence, Ageing, Heart, Woman, Inhalation, Atmosphere, International Organization (journal), Dementia, CPAP, OSA, Obstructive sleep apnea, Pressure, Obesity, FDA, OTC, Smoking, Arrhythmia, Sleep, Biocompatibility, Exhalation, CHF, Risk, International Organization for Standardization, Consultant, Type 2 diabetes, Frustration, Engineering, BMI, DSM-IV codes, Non-invasive ventilation, Type, National Council, Respiration, Medical device

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.

Key Points: 
  • CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.
  • We have had numerous inquiries asking for REMSleep regulatory status update.
  • REMSleep consultants are confident we will receive our 510(K) and we will never give up until we are successful.
  • REMSleep has addressed this problem by developing a novel CPAP nasal pillow interface that has been engineered to reduce pressure and enable better airflow.

Zealand Pharma Announces Financial Results for the Full Year 2023

Retrieved on: 
Tuesday, February 27, 2024
DREAM, F2, F1, Overweight, Obesity, Weight loss, Part, F3, Human, Boehringer Ingelheim, BMI, NASH, Fatty liver disease, Zealand Pharma

In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.

Key Points: 
  • In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.
  • In February 2024, Boehringer Ingelheim and Zealand Pharma announced positive results from the Phase 2 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).
  • In December 2023, Zealand submitted an NDA to the U.S. FDA for the treatment of adult patients with SBS dependent on parenteral support.
  • A recording of the event will be available following the call on the Investor section of Zealand’s website at https://www.zealandpharma.com/events/ .

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, February 22, 2024
EMANATE, New Drug Application, Investment, Obesity, BMI, Webcast, Initiate, BBS, Stage 2, Hyperpigmentation, Documentation, Polyphagia, European, GAAP, European Medicines Agency, PCSK1, Type, Type 2, G&A, LG Chem, BV, Completeness, Shanda, Bardet–Biedl syndrome, Clinical trial, LEPR, Medicaid, IND, Prescription, Research, Hunger, Acquisition, Quarter, EMA, MC4R, FDA, Prevalence, PMDA, Patient, POMC, Body mass index, Pharmaceutical industry

-- Acquired global rights to oral MC4R agonist LB54640 from LG Chem --

Key Points: 
  • ET --
    BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: As of December 31, 2023, cash, cash equivalents and short-term investments were approximately $275.8 million, as compared to $333.3 million as of December 31, 2022.
  • S,G&A Expenses: S,G&A expenses were $32.4 million in the fourth quarter of 2023 and $117.5 million for the year ended December 31, 2023, compared to $26.3 million in the fourth quarter of 2022 and $92.0 million for the year ended December 31, 2022.
  • ET today to review its fourth quarter and year end 2023 financial results and recent business activities.

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Retrieved on: 
Wednesday, February 21, 2024
Vamorolone, Catalyst Pharmaceuticals, NSAA, Safety, Prednisone, DMD, Growth, Duchenne muscular dystrophy, Neurology, Biomarker, BMI, Patient, LSM, JAMA Neurology, Pharmaceutical industry

Catalyst holds the exclusive rights to commercialize AGAMREE® (vamorolone) in North America.

Key Points: 
  • Catalyst holds the exclusive rights to commercialize AGAMREE® (vamorolone) in North America.
  • Based on the published study, Santhera has reported that the results of the VISION-DMD study support the long-term efficacy and safety profile of vamorolone and conclude that vamorolone was generally well tolerated, consistent with the 24-week study findings, as published previously in JAMA Neurology [2].
  • This study [VISION-DMD] was conducted to determine the efficacy and safety of vamorolone over 48 weeks and to study crossover participants (prednisone to vamorolone; placebo to vamorolone).
  • Improvements of motor outcomes seen with 6 mg/kg/d of vamorolone at 24 weeks of treatment were maintained to 48 weeks of treatment.

TEGNA Inc. Reports Fourth Quarter and Full-Year 2023 Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024
Social Media, TV and Radio, Media, Advertising, Communications, General Entertainment, Mobile Entertainment, Entertainment, Acquisition, Marketing, Total, Summer, FOX, AMS, Share repurchase, City, Culture, Growth, Super Bowl, Winter Olympic Games, Sale, ABC, Adjustment, Winter, GAAP, TEGNA, NBC, TGNA, BMI, Broadcast Music, Inc., IA Financial Group, Video game

TEGNA Inc. (NYSE: TGNA) today announced financial results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • TEGNA Inc. (NYSE: TGNA) today announced financial results for the fourth quarter and full-year ended December 31, 2023.
  • Since our third quarter earnings release on November 7, 2023, TEGNA has renewed multiple comprehensive retransmission consent agreements representing approximately 30 percent of our traditional subscribers.
  • 1 In analyzing fourth quarter 2023 results, investors should be reminded that TEGNA’s odd-to-even year results are negatively impacted by the absence of even-year political revenues.
  • Fourth quarter Adjusted EBITDA was down 28 percent compared to the fourth quarter of 2021 reflecting lower high-margin AMS and political revenue and higher programming expenses.

Diabetes Research Study in Santa Clarita Evaluating a New Approach To Helping Patients

Retrieved on: 
Monday, February 26, 2024
Women, Other Health, Seniors, Radiology, Men, Research, Family, Medical Devices, Hospitals, Consumer, Science, Managed Care, Cardiology, FDA, Biotechnology, Diabetes, Surgery, Health, Multimedia, Blood, Liver disease, Obesity, Stroke, Splenic infarction, DMR, Risk, Type 2 diabetes, BMI, Patient, Insulin, Medicine, Insulin resistance, Kidney disease, Duodenum

A new diabetes research study is available in Santa Clarita, Calif., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

Key Points: 
  • A new diabetes research study is available in Santa Clarita, Calif., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.
  • “For many people living with diabetes, controlling blood glucose levels is a difficult journey,” said Dr. Sina Tebi, Principal Investigator at Care Access - Santa Clarita.
  • The local setting provides residents of Santa Clarita and surrounding communities the option to participate in clinical studies close to home.
  • With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

Diabetes Research Study Evaluating a New Approach To Helping Patients Now Offered in Warwick

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Diabetes, Health, Women, Seniors, Men, Research, Family, Consumer, Science, Clinical Trials, Multimedia, Blood, Liver disease, Obesity, Cardiovascular disease, Stroke, Splenic infarction, DMR, Risk, Type 2 diabetes, BMI, Patient, Insulin, Medicine, Insulin resistance, Kidney disease, Duodenum, Medical device

A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

Key Points: 
  • A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.
  • (Photo: Business Wire)
    The combination of diabetes and obesity significantly increases one’s risk of heart attacks, stroke, liver disease, kidney disease, and other serious health problems.
  • Care Access is a global clinical research company helping to accelerate the future of medicine.
  • With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.